Fmoc-2-amino-6-methylbenzoic acid | 870150-57-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-2-amino-6-methylbenzoic acid
• 英文别名: 2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-methylbenzoic acid
• CAS: 870150-57-5
• 化学式: C₂₃H₁₉NO₄
• 分子量: 373.408
• InChiKey: GXUAWDMYWAUCOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  541.8±45.0 °C(Predicted)
• 密度：
  1.323±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  Fmoc-2-amino-6-methylbenzoic acid 、 美普他酚 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 生成
  参考文献：
  名称：

  甲吡唑苯甲酸酯作为前药的合成及其相对生物利用度。

  摘要：

  合成了三种甲氧萘酚苯甲酸酯（1-3）作为前药，以最大程度地降低甲氧嗪的首过效应并提高生物利用度。在这三种酯中，化合物3的生物利用度比母体甲哌嗪醇好。此外，使用大鼠原位闭环研究评估了前药3的相对区域生物利用度，这表明前药3在大鼠肠中具有更高的吸收功效。因此，前药3可能值得进一步开发。

  DOI：

  10.1016/j.bmcl.2005.03.039
• 作为产物：
  描述：

  氯甲酸-9-芴基甲酯 、 2-氨基-6-甲基苯甲酸 生成 Fmoc-2-amino-6-methylbenzoic acid
  参考文献：
  名称：

  甲吡唑苯甲酸酯作为前药的合成及其相对生物利用度。

  摘要：

  合成了三种甲氧萘酚苯甲酸酯（1-3）作为前药，以最大程度地降低甲氧嗪的首过效应并提高生物利用度。在这三种酯中，化合物3的生物利用度比母体甲哌嗪醇好。此外，使用大鼠原位闭环研究评估了前药3的相对区域生物利用度，这表明前药3在大鼠肠中具有更高的吸收功效。因此，前药3可能值得进一步开发。

  DOI：

  10.1016/j.bmcl.2005.03.039

文献信息

• Human testis expressed patched like protein
  申请人：Aeomica, Inc.

  公开号：EP1229046A2

  公开（公告）日：2002-08-07

  The invention provides isolated nucleic acids that encode HTPL, including two isoforms, and fragments thereof, vectors for propagating and expressing HTPL nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel HTPL isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human HTPL nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human HTPL gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the HTPL nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码 HTPL（包括两种异构体）的分离核酸及其片段、繁殖和表达 HTPL 核酸的载体、包含本发明核酸和载体的宿主细胞、新型 HTPL 异构体的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含人类 HTPL 核酸的转基因细胞和非人类生物体，以及靶向干扰人类 HTPL 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明核酸、蛋白质和抗体的药物制剂，以及基于本发明 HTPL 核酸、蛋白质和抗体的诊断、研究和治疗方法。
• A human protein kinase domain-containing protein
  申请人：Aeomica, Inc.

  公开号：EP1227156A2

  公开（公告）日：2002-07-31

  The invention provides isolated nucleic acids that encode a human protein kinase domain-containing portein (STTK), and fragments thereof, vectors for propagating and expressing STTK nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel STTK isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising STTK nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the STTK gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the STTK nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码含人蛋白激酶结构域的门冬氨酸（STTK）的分离核酸及其片段、用于繁殖和表达STTK核酸的载体、包含本发明核酸和载体的宿主细胞、新型STTK异构体的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含 STTK 核酸的转基因细胞和非人类生物体，以及定向破坏 STTK 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明核酸、蛋白质和抗体的药物制剂，以及基于本发明 STTK 核酸、蛋白质和抗体的诊断、研究和治疗方法。
• Human ralgds-like protein 3
  申请人：Aeomica, Inc.

  公开号：EP1229132A2

  公开（公告）日：2002-08-07

  The invention provides isolated nucleic acids that encode RGL3, and fragments thereof, vectors for propagating and expressing RGL3 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel RGL3 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human RGL3 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human RGL3 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the RGL3 nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码RGL3的分离核酸及其片段、用于繁殖和表达RGL3核酸的载体、包含本发明核酸和载体的宿主细胞、新型RGL3异构体的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含人类 RGL3 核酸的转基因细胞和非人类生物体，以及靶向破坏人类 RGL3 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明核酸、蛋白质和抗体的药物制剂，以及基于本发明RGL3核酸、蛋白质和抗体的诊断、研究和治疗方法。
• Human gtp-rho binding protein 2
  申请人：Aeomica, Inc.

  公开号：EP1231216A2

  公开（公告）日：2002-08-14

  The invention provides isolated nucleic acids that encode human GRBP2, and fragments thereof, vectors for propagating and expressing human GRBP2 nucleic acids, host cells comprising the inucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the human GRBP2, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human GRBP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human GRBP2 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human GRBP2 nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码人GRBP2的分离核酸及其片段、用于繁殖和表达人GRBP2核酸的载体、包含本发明核酸和载体的宿主细胞、人GRBP2的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含人 GRBP2 核酸的转基因细胞和非人类生物体，以及靶向破坏人 GRBP2 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明的核酸、蛋白质和抗体的药物制剂，以及基于本发明的人GRBP2核酸、蛋白质和抗体的诊断、研究和治疗方法。
• Human posh-like protein 1
  申请人：Aeomica, Inc.

  公开号：EP1239051A2

  公开（公告）日：2002-09-11

  The invention provides isolated nucleic acids that encode human POSHL1, and fragments thereof, vectors for propagating and expressing human POSHL1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel human POSHL1 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human POSHL1 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human POSHL1 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human POSHL1 nucleic acids, proteins, and antibodies of the present invention.

  本发明提供了编码人POSHL1的分离核酸及其片段、用于繁殖和表达人POSHL1核酸的载体、包含本发明核酸和载体的宿主细胞、新型人POSHL1异构体的蛋白质、蛋白质片段和蛋白质融合体及其抗体。本发明进一步提供了包含人 POSHL1 核酸的转基因细胞和非人类生物体，以及靶向破坏人 POSHL1 基因内源直向同源物的转基因细胞和非人类生物体。本发明进一步提供了本发明的核酸、蛋白质和抗体的药物制剂，以及基于本发明的人POSHL1核酸、蛋白质和抗体的诊断、研究和治疗方法。